GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Cyclically Adjusted Price-to-FCF

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Cyclically Adjusted Price-to-FCF : 32.84 (As of Jun. 10, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Price-to-FCF?

As of today (2024-06-10), Shenzhenlubris Pharmaceuticals Co's current share price is ¥27.26. Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ¥0.83. Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF for today is 32.84.

The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

SZSE:002294' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 25.56   Med: 38.38   Max: 91.37
Current: 33.03

During the past years, Shenzhenlubris Pharmaceuticals Co's highest Cyclically Adjusted Price-to-FCF was 91.37. The lowest was 25.56. And the median was 38.38.

SZSE:002294's Cyclically Adjusted Price-to-FCF is ranked better than
57.2% of 236 companies
in the Medical Devices & Instruments industry
Industry Median: 42.675 vs SZSE:002294: 33.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Shenzhenlubris Pharmaceuticals Co's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ¥0.104. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ¥0.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.15 38.33 33.45 39.24 39.72

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.47 36.53 35.73 39.72 35.27

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF falls into.



Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=27.26/0.83
=32.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Shenzhenlubris Pharmaceuticals Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.104/115.2271*115.2271
=0.104

Current CPI (Mar. 2024) = 115.2271.

Shenzhenlubris Pharmaceuticals Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.213 98.200 0.250
201409 0.180 98.900 0.210
201412 0.259 99.000 0.301
201503 0.156 99.900 0.180
201506 0.127 99.500 0.147
201509 0.202 100.500 0.232
201512 0.292 100.600 0.334
201603 0.250 102.200 0.282
201606 0.292 101.400 0.332
201609 0.364 102.400 0.410
201612 0.228 102.600 0.256
201703 0.364 103.200 0.406
201706 0.197 103.100 0.220
201709 0.246 104.100 0.272
201712 0.271 104.500 0.299
201803 0.189 105.300 0.207
201806 0.191 104.900 0.210
201809 0.462 106.600 0.499
201812 0.112 106.500 0.121
201903 0.354 107.700 0.379
201906 0.246 107.700 0.263
201909 0.303 109.800 0.318
201912 0.092 111.200 0.095
202003 0.336 112.300 0.345
202006 0.392 110.400 0.409
202009 -0.040 111.700 -0.041
202012 0.022 111.500 0.023
202103 -0.030 112.662 -0.031
202106 0.081 111.769 0.084
202109 0.456 112.215 0.468
202112 0.182 113.108 0.185
202203 -0.007 114.335 -0.007
202206 0.113 114.558 0.114
202209 0.135 115.339 0.135
202212 0.096 115.116 0.096
202303 0.020 115.116 0.020
202306 0.104 114.558 0.105
202309 -0.114 115.339 -0.114
202312 0.136 114.781 0.137
202403 0.104 115.227 0.104

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Shenzhenlubris Pharmaceuticals Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines